IP Library Granted Patent US 7,144,985
Granted Patent B2
US 7,144,985 · App. 10/308,393 · Granted Dec 5, 2006

Methods and reagents for diagnosis and treatment of diabetes

Assignee: Metabolex, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,144,985
App. No.
10/308,393
Granted
Dec 5, 2006
Kind
B2
Abstract

The invention relates to methods of determining islet cell activity by detecting the level of Archipelin or a fragment thereof and comparing the level to a baseline level or range associated with a known islet cell activity. Such methods are useful in diagnosing and studying the development of diabetes.

Claims (12)

1. A method of determining islet cell-specific activity in an individual, the method comprising,

detecting the level of a polypeptide comprising SEQ ID NO:9 in a sample wherein the said sample comprises human blood from the individual, and

determining islet cell-specific activity in the individual by comparing the level of the polypeptide in the sample to a baseline value or range associated with a known islet cell activity wherein said islet cell activity is associated with the ability of the islet cell to produce said polypeptide.

2. The method of claim 1 , wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14.

3. The method of claim 1 , wherein the polypeptide comprises SEQ ID NO:2.

4. The method of claim 1 , wherein the polypeptide is detected by an antibody.

5. The method of claim 1 , wherein the baseline or range is representative of the level of the polypeptide in a non-diabetic individual.

6. The method of claim 1 , wherein the level of the polypeptide in the individual is altered compared to a level of the polypeptide in a non-diabetic individual.

7. The method of claim 6 , wherein the level of the polypeptide in the individual is lower than a level of the polypeptide in a non-diabetic individual.

8. The method of claim 6 , wherein the altered level of the polypeptide in the individual is higher than a level of the polypeptide in a non-diabetic individual.

9. The method of claim 6 , wherein the level of the polypeptide in the individual is less than 50% of the level from the non-diabetic individual.

10. The method of claim 6 , wherein the level of the polypeptide in the individual is at least 150% of the level from the non-diabetic individual.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Aug 7, 2015
From: SILICON VALLEY BANK; OXFORD FINANCE LLC
To: CYMABAY THERAPEUTICS, INC.
Reel/Frame 036307/0406 →
SECURITY AGREEMENT Recorded Nov 22, 2013
From: CYMABAY THERAPEUTICS, INC.
To: SILICON VALLEY BANK; OXFORD FINANCE LLC
Reel/Frame 031710/0508 →
CHANGE OF NAME Recorded Oct 30, 2013
From: METABOLEX, INC.
To: CYMABAY THERAPEUTICS, INC.
Reel/Frame 031516/0341 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2003
From: JOHNSON, JEFFREY D.; BLUME, JOHN E.; PALMA, JOHN F.; ZHOU, YUN-PING
To: METABOLEX, INC.
Reel/Frame 013773/0924 →
Continuity (2)
Provisional Application 6033663300 · Dec 3, 2001
Related Publication 20030202976A1 · Oct 30, 2003